Home/Filings/4/0001209191-23-028886
4//SEC Filing

Harper Sean E 4

Accession 0001209191-23-028886

CIK 0001962918other

Filed

May 10, 8:00 PM ET

Accepted

May 11, 9:16 PM ET

Size

18.5 KB

Accession

0001209191-23-028886

Insider Transaction Report

Form 4
Period: 2023-05-09
Harper Sean E
10% Owner
Transactions
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    2023-05-092,445,7860 total
    Common Stock (2,445,786 underlying)
  • Conversion

    Series C Redeemable Convertible Preferred Stock

    2023-05-092,038,1480 total
    Common Stock (2,038,148 underlying)
  • Conversion

    Common Stock

    2023-05-09+8,540,7298,540,729 total
  • Purchase

    Common Stock

    2023-05-09$18.00/sh+1,250,000$22,500,0009,790,729 total
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    2023-05-094,056,7950 total
    Common Stock (4,056,795 underlying)
Transactions
  • Conversion

    Common Stock

    2023-05-09+8,540,7298,540,729 total
  • Purchase

    Common Stock

    2023-05-09$18.00/sh+1,250,000$22,500,0009,790,729 total
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    2023-05-094,056,7950 total
    Common Stock (4,056,795 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    2023-05-092,445,7860 total
    Common Stock (2,445,786 underlying)
  • Conversion

    Series C Redeemable Convertible Preferred Stock

    2023-05-092,038,1480 total
    Common Stock (2,038,148 underlying)
Transactions
  • Conversion

    Common Stock

    2023-05-09+8,540,7298,540,729 total
  • Purchase

    Common Stock

    2023-05-09$18.00/sh+1,250,000$22,500,0009,790,729 total
  • Conversion

    Series A Redeemable Convertible Preferred Stock

    2023-05-094,056,7950 total
    Common Stock (4,056,795 underlying)
  • Conversion

    Series B Redeemable Convertible Preferred Stock

    2023-05-092,445,7860 total
    Common Stock (2,445,786 underlying)
  • Conversion

    Series C Redeemable Convertible Preferred Stock

    2023-05-092,038,1480 total
    Common Stock (2,038,148 underlying)
Footnotes (6)
  • [F1]Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration.
  • [F2]Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. Beth C. Seidenberg and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any.
  • [F3]This report on Form 4 is jointly filed by Westlake Fund II, Westlake GP II and Sean E. Harper. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of such person's or entity's pecuniary interest therein, if any. Westlake Fund II has designated a representative, Beth C. Seidenberg, a Managing Director of Westlake GP II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose.
  • [F4]Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the "IPO").
  • [F5]Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock.
  • [F6]Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

Issuer

ACELYRIN, Inc.

CIK 0001962918

Entity typeother

Related Parties

1
  • filerCIK 0001541946

Filing Metadata

Form type
4
Filed
May 10, 8:00 PM ET
Accepted
May 11, 9:16 PM ET
Size
18.5 KB